VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Harvest Investment Services LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,810 shares of the company’s stock, valued at approximately $690,000. A number of other hedge funds […]
E Fund Management Co. Ltd. trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 13.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,834 shares of the company’s stock after selling 1,378 shares during the period. E Fund Management Co. Ltd.’s […]
Chicago Partners Investment Group LLC trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 14.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,157 shares of the company’s stock after selling 1,002 shares during the period. Chicago Partners […]
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Equities research analysts at Cantor Fitzgerald reduced their FY2023 earnings estimates for Vaxcyte in a research note issued on Tuesday, November 7th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn ($3.33) per share for the year, down from their previous estimate of ($3.05). Cantor […]